NEW YORK (GenomeWeb News) - PrognosDx Health has signed an exclusive, worldwide license for the patent rights associated with epigenetics technology developed at the University of California, Los Angeles, the company said today.

The technology, developed by Siavash Kurdistani and David Seligson at UCLA, is based on the predictive power of global histone modification patterns and "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.